NCT04487860

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 327 (actual)
• Sponsor: Ache Laboratorios Farmaceuticos S.A. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.

Conditions

• Non-segmental Vitiligo

Interventions

Type	Name	Description
DRUG	AS012	oral administration
DRUG	Placebo	oral administration

Timeline

• Start date: 2021-01-13
• Primary completion: 2022-05-20
• Completion: 2023-02-27
• First posted: 2020-07-27
• Last updated: 2025-03-10
• Results posted: 2025-03-10

Locations

31 sites across 2 countries: United States, India

Regulatory

• FDA-regulated drug study